title: Inhibition of Ras p21 synthesis by antisense undecamers with uniform and specifically arranged phosphorothioate linkages.
abstract: The design of chimeric oligodeoxynucleotides (ODNs) in which certain phosphodiester linkages are replaced by phosphorothioate (PS) aims to decrease non-sequence-specific effects of uniform PS ODNs and to preserve the PS-provided protection against exo- and endonucleases. This study has, for the fist time, directly compared the differences in nuclease resistance, cellular uptake, antisense potency and sequence specificity of PS and end-capped, pyrimidine-protected (PPS) undecamer ODNs, that are complementary to the initiation codon region of human Ha-ras mRNA. At concentrations above 5 microM, both PS and PPS undecamers were moderately and equally stable for over 48 h in complete medium with RS485 cells overexpressing Ha-ras. They were completely stable at 0.4 microM when complexed with Lipofectin reagent that enhanced cellular uptake up to 9-fold. Both the antisense PPS and PS undecamers produced well-defined inhibition of Ras p21 synthesis in both cell-free and cell-based assays. However, non-sequence-specific effects of the uniform phosphorothioates were still significant. In contrast, the antisense PPS undecamer, when delivered to RS485 cells with Lipofectin reagent, inhibits human Ras p21 synthesis by more than 90% at a concentration of 3.2 microM, while the effect of controls with inverted, mismatched or scrambled sequence was minimal (5% or less) on p21 synthesis and RS485 cell growth.
authors.affiliation: Department of Otolaryngology, Georgetown University Medical Center, Washington, DC 20007, USA.
authors.forename: A
authors.initials: A
authors.lastname: Rait
authors.forename: E
authors.initials: E
authors.lastname: Uhlmann
authors.forename: A
authors.initials: A
authors.lastname: Peyman
authors.forename: D W
authors.initials: DW
authors.lastname: Will
authors.forename: E H
authors.initials: EH
authors.lastname: Chang
mesh_terms: D002460:Cell Line / Q000187:drug effects; D011905:Genes, ras; D006801:Humans; D009690:Nucleic Acid Conformation; D016376:Oligonucleotides, Antisense / Q000737:chemistry* / Q000494:pharmacology; D015689:Oncogene Protein p21(ras) / Q000037:antagonists & inhibitors* / Q000096:biosynthesis*; D012333:RNA, Messenger / Q000378:metabolism; D011993:Recombinant Fusion Proteins / Q000737:chemistry / Q000494:pharmacology; D013329:Structure-Activity Relationship; D013873:Thionucleotides / Q000737:chemistry
chemical_list: D016376:Oligonucleotides, Antisense; D012333:RNA, Messenger; D011993:Recombinant Fusion Proteins; D013873:Thionucleotides; D015689:Oncogene Protein p21(ras)